Neuphoria Therapeutics Inc.
Clinical-stage biotech developing therapies for neuropsychiatric disorders.
NEUP | US
Overview
Corporate Details
- ISIN(s):
- US64136E1029 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 100 SUMMIT DR, 1803 BURLINGTON
- Website:
- https://www.neuphoriatx.com/
- Sector:
- Manufacturing
Description
Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing therapies for individuals affected by neuropsychiatric disorders. The company focuses on discovering and developing novel allosteric ion channel modulators to address unmet needs in mental health. Its lead product candidate, BNC210, is a first-in-class, anti-anxiety medication designed to restore balance in brain chemistry through a novel mechanism of action. BNC210 aims to provide rapid relief from anxiety symptoms without the common side effects of sedation, cognitive impairment, or addiction potential. The therapy is developed in a proprietary tablet formulation that allows for flexible, as-needed or regular dosing.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Neuphoria Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Neuphoria Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Neuphoria Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
